706 related articles for article (PubMed ID: 31893514)
1. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
[TBL] [Abstract][Full Text] [Related]
2. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
[TBL] [Abstract][Full Text] [Related]
3. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
[TBL] [Abstract][Full Text] [Related]
4. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
George LA; Monahan PE; Eyster ME; Sullivan SK; Ragni MV; Croteau SE; Rasko JEJ; Recht M; Samelson-Jones BJ; MacDougall A; Jaworski K; Noble R; Curran M; Kuranda K; Mingozzi F; Chang T; Reape KZ; Anguela XM; High KA
N Engl J Med; 2021 Nov; 385(21):1961-1973. PubMed ID: 34788507
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
Fong S; Yates B; Sihn CR; Mattis AN; Mitchell N; Liu S; Russell CB; Kim B; Lawal A; Rangarajan S; Lester W; Bunting S; Pierce GF; Pasi KJ; Wong WY
Nat Med; 2022 Apr; 28(4):789-797. PubMed ID: 35411075
[TBL] [Abstract][Full Text] [Related]
6. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
[TBL] [Abstract][Full Text] [Related]
7. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
8. Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy.
Fonck C; Su C; Arens J; Koziol E; Srimani J; Henshaw J; Van Tuyl A; Chandra S; Vettermann C; O'Neill CA
Gene Ther; 2023 Aug; 30(7-8):581-586. PubMed ID: 35132205
[TBL] [Abstract][Full Text] [Related]
9. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
[TBL] [Abstract][Full Text] [Related]
11. Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.
Zhang L; Handyside B; Murphy R; Sihn CR; Xie L; Vitelli C; Harmon D; Sisó S; Liu S; Bullens S; Bunting S; Fong S
Mol Ther Methods Clin Dev; 2020 Jun; 17():13-20. PubMed ID: 31890737
[TBL] [Abstract][Full Text] [Related]
12. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
17. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.
Rosen S; Tiefenbacher S; Robinson M; Huang M; Srimani J; Mackenzie D; Christianson T; Pasi KJ; Rangarajan S; Symington E; Giermasz A; Pierce GF; Kim B; Zoog SJ; Vettermann C
Blood; 2020 Nov; 136(22):2524-2534. PubMed ID: 32915950
[TBL] [Abstract][Full Text] [Related]
18. Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood.
Zhang L; Yates B; Murphy R; Liu S; Xie L; Handyside B; Sihn CR; Bouwman T; Galicia N; Tan D; Fonck C; Arens J; Clark A; Zhang W; Chandra S; Srimani J; Holcomb J; Van Tuyl A; Henshaw J; Vettermann C; Siso S; Su C; Bullens S; Bunting S; O'Neill C; Fong S
Mol Ther Methods Clin Dev; 2022 Sep; 26():519-531. PubMed ID: 36092364
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers.
Sihn CR; Handyside B; Liu S; Zhang L; Murphy R; Yates B; Xie L; Torres R; Russell CB; O'Neill CA; Pungor E; Bunting S; Fong S
Mol Ther Methods Clin Dev; 2022 Mar; 24():142-153. PubMed ID: 35036471
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M
Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
